IT8468021A0 - Agente anti virale e procedimento per inibire la propagazione di un virus - Google Patents

Agente anti virale e procedimento per inibire la propagazione di un virus

Info

Publication number
IT8468021A0
IT8468021A0 IT8468021A IT6802184A IT8468021A0 IT 8468021 A0 IT8468021 A0 IT 8468021A0 IT 8468021 A IT8468021 A IT 8468021A IT 6802184 A IT6802184 A IT 6802184A IT 8468021 A0 IT8468021 A0 IT 8468021A0
Authority
IT
Italy
Prior art keywords
virus
propagation
inhibit
procedure
viral agent
Prior art date
Application number
IT8468021A
Other languages
English (en)
Other versions
IT1179144B (it
IT8468021A1 (it
Inventor
Kaji Akira
Original Assignee
Akiri Kaji
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP58192350A external-priority patent/JPH0740934B2/ja
Priority claimed from JP59049321A external-priority patent/JPS60193922A/ja
Application filed by Akiri Kaji filed Critical Akiri Kaji
Publication of IT8468021A0 publication Critical patent/IT8468021A0/it
Publication of IT8468021A1 publication Critical patent/IT8468021A1/it
Application granted granted Critical
Publication of IT1179144B publication Critical patent/IT1179144B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1133—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against herpetoviridae, e.g. HSV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
IT68021/84A 1983-10-17 1984-10-16 Agente anti virale e procedimento per inibire la propagazione di un virus IT1179144B (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP58192350A JPH0740934B2 (ja) 1983-10-17 1983-10-17 ウイルス増殖阻害方法
JP59049321A JPS60193922A (ja) 1984-03-16 1984-03-16 抗ウイルス剤
MT957A MTP957B (en) 1983-10-17 1984-12-12 Method for inhibiting viral propagation and anti-viral agent

Publications (3)

Publication Number Publication Date
IT8468021A0 true IT8468021A0 (it) 1984-10-16
IT8468021A1 IT8468021A1 (it) 1986-04-16
IT1179144B IT1179144B (it) 1987-09-16

Family

ID=39877713

Family Applications (1)

Application Number Title Priority Date Filing Date
IT68021/84A IT1179144B (it) 1983-10-17 1984-10-16 Agente anti virale e procedimento per inibire la propagazione di un virus

Country Status (18)

Country Link
US (1) US4689320A (it)
AT (1) AT392081B (it)
AU (1) AU578625B2 (it)
BE (1) BE900827A (it)
CH (1) CH667593A5 (it)
DE (1) DE3437852A1 (it)
DK (1) DK168061B1 (it)
FR (1) FR2553420B1 (it)
GB (1) GB2148302B (it)
IE (1) IE57987B1 (it)
IT (1) IT1179144B (it)
LU (1) LU85594A1 (it)
MT (1) MTP957B (it)
NL (1) NL8403163A (it)
NZ (1) NZ209840A (it)
PH (1) PH21629A (it)
SE (1) SE466482B (it)
SG (1) SG31088G (it)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986005516A1 (en) * 1985-03-21 1986-09-25 Duke University Parasite-derived resistance
US5580716A (en) * 1985-03-21 1996-12-03 Stephen A. Johnston Parasite-derived resistance
ATE124993T1 (de) * 1986-04-02 1995-07-15 Pioneer Hi Bred Int Pflanzen, resistent gegen den anti-sens rns aufweisenden virus.
US5194428A (en) * 1986-05-23 1993-03-16 Worcester Foundation For Experimental Biology Inhibition of influenza virus replication by oligonucleotide phosphorothioates
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US5637573A (en) * 1986-05-23 1997-06-10 Agrawal; Sudhir Influenza virus replication inhibiting oligonucleotide analogues and their pharmaceutical compositions
US5834185A (en) * 1986-10-28 1998-11-10 Johns Hopkins University Formation of triple helix complexes of single stranded nucleic acids using nucleoside oligomers which comprise pyrimidine analogs, triple helix complexes formed thereby and oligomers used in their formation
US4904582A (en) * 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
DE68929343T2 (de) * 1988-02-16 2002-09-12 Greatbatch Gen Aid Ltd Modifizierte Zellen mit Resistenz gegen Retroviralinfektionen
US5004810A (en) * 1988-09-30 1991-04-02 Schering Corporation Antiviral oligomers
US5098890A (en) * 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5693622A (en) * 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
JP3250802B2 (ja) * 1989-03-21 2002-01-28 バイカル・インコーポレイテッド 脊椎動物における外因性ポリヌクレオチド配列の発現
US6867195B1 (en) * 1989-03-21 2005-03-15 Vical Incorporated Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
US6214804B1 (en) 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
AU5931290A (en) * 1989-06-20 1991-01-08 Meiogenics, Inc. Nuclease resistant, single-stranded, non-naturally occurring nucleic acid molecules
CA2065294A1 (en) * 1989-09-01 1991-03-02 Bruno Calabretta Antisense oligonucleotides to c-abl proto-oncogene
EP0500799B1 (en) * 1989-11-16 1998-01-14 Duke University Particle mediated transformation of animal skin tissue cells
US5177198A (en) * 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US6339066B1 (en) 1990-01-11 2002-01-15 Isis Pharmaceuticals, Inc. Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
KR927003044A (ko) * 1990-01-11 1992-12-17 크리스토퍼 케이. 미라벨리 Rna 활성과 유전자 발현을 검출하고 조절하는 조성물 및 그 방법
US6399754B1 (en) 1991-12-24 2002-06-04 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides
US5852182A (en) * 1990-01-11 1998-12-22 Isis Pharmaceuticals Inc. Thiol-derivatized oligonucleosides
US5459255A (en) * 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US6395492B1 (en) * 1990-01-11 2002-05-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US6114513A (en) * 1990-01-11 2000-09-05 Isis Pharmaceuticals, Inc. Thiol-derivatized oligonucleotides
US6005087A (en) * 1995-06-06 1999-12-21 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US5859221A (en) * 1990-01-11 1999-01-12 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US6753423B1 (en) 1990-01-11 2004-06-22 Isis Pharmaceuticals, Inc. Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
US20040142899A1 (en) * 1990-01-11 2004-07-22 Isis Pharmaceuticals, Inc. Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
WO1992003568A1 (en) * 1990-08-13 1992-03-05 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US7037646B1 (en) 1990-01-11 2006-05-02 Isis Pharmaceuticals, Inc. Amine-derivatized nucleosides and oligonucleosides
US5872232A (en) * 1990-01-11 1999-02-16 Isis Pharmaceuticals Inc. 2'-O-modified oligonucleotides
US5248670A (en) * 1990-02-26 1993-09-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotides for inhibiting herpesviruses
US5514577A (en) * 1990-02-26 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide therapies for modulating the effects of herpes viruses
US6228844B1 (en) 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US6706694B1 (en) 1990-03-21 2004-03-16 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
US20030186913A1 (en) * 1990-03-21 2003-10-02 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
US5610050A (en) * 1990-04-20 1997-03-11 The General Hospital Corporation Methods of preventing viral replication
US5639595A (en) * 1990-05-01 1997-06-17 Isis Phamaceuticals, Inc. Identification of novel drugs and reagents
WO1991018088A1 (en) * 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5135917A (en) * 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
US6262241B1 (en) * 1990-08-13 2001-07-17 Isis Pharmaceuticals, Inc. Compound for detecting and modulating RNA activity and gene expression
AU652577B2 (en) * 1990-08-14 1994-09-01 Isis Pharmaceuticals, Inc. Inhibition of influenza virus type A, Ann Arbor strain H2N2 by antisense oligonucleotides
WO1992003051A1 (en) * 1990-08-15 1992-03-05 Genta Incorporated Inhibition of herpesviridae infection by antisense oligonucleotides
US5595978A (en) * 1990-08-16 1997-01-21 Isis Pharmaceuticals, Inc. Composition and method for treatment of CMV retinites
CA2092711A1 (en) * 1990-09-21 1992-03-22 Laure Aurelian Compositions and methods for inhibiting growth or replication of viruses
WO1992004903A1 (en) * 1990-09-21 1992-04-02 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Method of inhibiting viral production
US5942389A (en) * 1990-10-19 1999-08-24 Board Of Trustees Of The University Of Illinois Genes and genetic elements associated with sensitivity to cisplatin
WO1992013972A1 (en) * 1991-02-11 1992-08-20 Thomas Jefferson University Genetically engineered bacteria to identify and produce medically important agents
US5965722A (en) * 1991-05-21 1999-10-12 Isis Pharmaceuticals, Inc. Antisense inhibition of ras gene with chimeric and alternating oligonucleotides
JPH06507911A (ja) * 1991-05-31 1994-09-08 ジンタ・インコーポレイテッド 中性オリゴマーを経皮投与するための組成物及び供給系
US7119184B2 (en) * 1991-08-12 2006-10-10 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US6369209B1 (en) 1999-05-03 2002-04-09 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
US8153602B1 (en) 1991-11-19 2012-04-10 Isis Pharmaceuticals, Inc. Composition and methods for the pulmonary delivery of nucleic acids
EP0644889A4 (en) * 1991-12-24 1996-01-10 Isis Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR MODULATION OF -g (b) -AMYLOID.
US6033909A (en) * 1992-01-22 2000-03-07 Hoechst Aktiengesellschaft Oligonucleotide analogs, their preparation and use
US6537973B1 (en) 1992-03-16 2003-03-25 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of protein kinase C
US5643780A (en) * 1992-04-03 1997-07-01 Isis Pharmaceuticals, Inc. Compositions and methods for modulating RNA activity through modification of the 5' cap structure of RNA
US6521601B1 (en) * 1992-04-14 2003-02-18 Signal Pharmaceuticals, Inc. Method and composition for inhibition of viral replication
US6806084B1 (en) * 1992-06-04 2004-10-19 The Regents Of The University Of California Methods for compositions for in vivo gene delivery
US6346614B1 (en) 1992-07-23 2002-02-12 Hybridon, Inc. Hybrid oligonucleotide phosphorothioates
TW244371B (it) * 1992-07-23 1995-04-01 Tri Clover Inc
RU95104940A (ru) * 1992-07-27 1997-01-10 Хайбрайдон Способ введения в олигонуклеотид алкилфосфонотиоатной или арилфосфонотиоатной межнуклеотидной связи, способ получения олигонуклеотида, олигонуклеотиды, способ ингибирования генной экспрессии, способ лечения
US5985558A (en) * 1997-04-14 1999-11-16 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
AU685074B2 (en) * 1992-12-14 1998-01-15 Start Technology Partnership Administration of oligonucleotides antisense to dopamine receptor MRNA for diagnosis and treatment of neurological pathologies
NZ261976A (en) * 1993-01-21 1997-11-24 Hybridon Inc Triplex-forming oligonucleotides
US20040087521A1 (en) * 1993-03-18 2004-05-06 Merck & Co., Inc. Nucleic acid pharmaceuticals-influenza matrix
US5739309A (en) * 1993-07-19 1998-04-14 Gen-Probe Incorporated Enhancement of oligonucleotide inhibition of protein production, cell proliferation and / or multiplication of infectious disease pathogens
EP0714436B1 (en) * 1993-07-19 2003-05-07 Gen-Probe Incorporated Oligonucleotides with activity against human immunodeficiency virus
US6653458B1 (en) 1993-09-03 2003-11-25 Isis Pharmaceuticals, Inc. Modified oligonucleotides
ATE247128T1 (de) 1993-09-03 2003-08-15 Isis Pharmaceuticals Inc Aminoderivatisierte nukleoside und oligonukleoside
US5837852A (en) * 1993-10-14 1998-11-17 Bristol-Myers Squibb Company Capped nucleic acid oligomers that inhibit cap-dependent transcription of the influenza virus endonuclease
US6995008B1 (en) 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
IL112820A0 (en) * 1994-03-07 1995-05-26 Merck & Co Inc Coordinate in vivo gene expression
WO1995030746A1 (en) * 1994-05-10 1995-11-16 The General Hospital Corporation Antisense inhibition of hepatitis c virus
US5733781A (en) 1994-07-19 1998-03-31 Gen-Probe Incorporated Oligonucleotides and methods for inhibiting propagation of human immunodeficiency virus
EP0818202A4 (en) * 1994-09-29 2000-05-10 Npp Farmek DNA-RNA HYBRID AND DNA PREPARATION, PROCESSES FOR OBTAINING THE SAME AND PREPARATION THEREOF FROM STURGEON MILK, AND PHARMACEUTICAL COMPOUND BASED ON THE DNA-RNA HYBRID
US5750674A (en) * 1995-05-23 1998-05-12 Hybridon, Inc. Methods and compounds for the stereoselective enrichment of oligonucleotide diastereomers and oligonucleotides thereby produced
US6117993A (en) * 1995-05-23 2000-09-12 Hybridon, Inc. Synthons for oligonucleotide synthesis
US5693773A (en) * 1995-06-07 1997-12-02 Hybridon Incorporated Triplex-forming antisense oligonucleotides having abasic linkers targeting nucleic acids comprising mixed sequences of purines and pyrimidines
US5856099A (en) * 1996-05-21 1999-01-05 Isis Pharmaceuticals, Inc. Antisense compositions and methods for modulating type I interleukin-1 receptor expression
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US5885834A (en) * 1996-09-30 1999-03-23 Epstein; Paul M. Antisense oligodeoxynucleotide against phosphodiesterase
US6001991A (en) * 1996-10-04 1999-12-14 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression
US6319906B1 (en) 1996-12-31 2001-11-20 Isis Pharmaceuticals Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US6077833A (en) * 1996-12-31 2000-06-20 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US20040023917A1 (en) * 1996-12-31 2004-02-05 Bennett C. Frank Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US7235653B2 (en) * 1996-12-31 2007-06-26 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
EP1012331B1 (en) 1997-07-01 2006-03-29 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US5877309A (en) * 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US20070149472A1 (en) * 1997-08-13 2007-06-28 Mckay Robert Antisense oligonucleotide compositions and methods for the modulation of jnk proteins
US6809193B2 (en) 1997-08-13 2004-10-26 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US6306831B1 (en) 1997-09-12 2001-10-23 Qik Technologies, Inc. Transplacental delivery of oligonucleotides
US6232463B1 (en) 1997-10-09 2001-05-15 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
CA2513336A1 (en) * 1998-03-20 1999-09-30 Benitec Australia Ltd. Control of gene expression in a non-human eukaryotic cell, tissue or organ
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US6841539B1 (en) 1998-05-21 2005-01-11 Isis Pharmaceuticals, Inc. Compositions and methods for topical delivery of oligonucleotides
WO1999060012A1 (en) 1998-05-21 1999-11-25 Isis Pharmaceuticals, Inc. Compositions and methods for non-parenteral delivery of oligonucleotides
US6277967B1 (en) 1998-07-14 2001-08-21 Isis Pharmaceuticals, Inc. Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages
US6242589B1 (en) 1998-07-14 2001-06-05 Isis Pharmaceuticals, Inc. Phosphorothioate oligonucleotides having modified internucleoside linkages
US6867294B1 (en) * 1998-07-14 2005-03-15 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6015676A (en) * 1998-07-31 2000-01-18 Epiclone Inc. Method for knocking out gene transcripts by covalently binding of an anti-sense probe
RU2233844C2 (ru) 1999-02-12 2004-08-10 Санкио Компани Лимитед Новые нуклеозидные и олигонуклеотидные аналоги
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
JP4151751B2 (ja) * 1999-07-22 2008-09-17 第一三共株式会社 新規ビシクロヌクレオシド類縁体
US6423885B1 (en) * 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
US20010011126A1 (en) * 1999-09-10 2001-08-02 Bock Elisabeth Marianne Neurogenic compositions and methods
AU2001276691A1 (en) * 2000-08-03 2002-02-18 Matsushita Electric Industrial Co., Ltd. Brushless motor and method of manufacturing the brushless motor
US20030096770A1 (en) * 2001-07-11 2003-05-22 Krotz Achim H. Enhancement of the stability of oligonucleotides comprising phosphorothioate linkages by addition of water-soluble antioxidants
US20030191075A1 (en) * 2002-02-22 2003-10-09 Cook Phillip Dan Method of using modified oligonucleotides for hepatic delivery
US7704965B2 (en) * 2002-06-26 2010-04-27 The Penn State Research Foundation Methods and materials for treating human papillomavirus infections
US20040009483A1 (en) * 2002-07-12 2004-01-15 Ilsley Diane D. Method of linear mRNA amplification using total RNA
EP1546344A4 (en) * 2002-09-18 2007-10-03 Isis Pharmaceuticals Inc EFFICIENT REDUCTION OF TARGET RNA USING OLIGOMERIC COMPOUNDS WITH SINGLE AND DOUBLE STRAPS
CA2504929C (en) 2002-11-05 2014-07-22 Charles Allerson Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
CA2514912A1 (en) * 2003-02-05 2004-08-26 University Of Massachusetts Rnai targeting of viruses
US8084432B2 (en) 2003-02-13 2011-12-27 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of pouchitis
US7897582B2 (en) * 2003-05-23 2011-03-01 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US7960355B2 (en) * 2003-05-23 2011-06-14 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of the expression of B7 protein
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
WO2005121372A2 (en) * 2004-06-03 2005-12-22 Isis Pharmaceuticals, Inc. Double strand compositions comprising differentially modified strands for use in gene modulation
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
CA2660052A1 (en) * 2006-08-04 2008-02-07 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of jnk proteins
EP2432499A2 (en) 2009-05-20 2012-03-28 Schering Corporation Modulation of pilr receptors to treat microbial infections
WO2011084357A1 (en) 2009-12-17 2011-07-14 Schering Corporation Modulation of pilr to treat immune disorders
EP3052512A4 (en) 2013-09-30 2017-02-22 Geron Corporation Phosphorodiamidate backbone linkage for oligonucleotides
CN105532575A (zh) * 2016-01-14 2016-05-04 中国科学院昆明动物研究所 一种单纯疱疹病毒感染树鼩动物模型的构建、评估方法及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1107929A (en) * 1965-11-14 1968-03-27 Yissum Res Dev Co Organotin derivatives of natural and synthetic polymers
JPS5735516A (en) * 1980-08-11 1982-02-26 Yamasa Shoyu Co Ltd Agent for increasing radiosensitivity or agent for increasing effect of substance having activity similar to radiation
JPS5767518A (en) * 1980-09-17 1982-04-24 Yamasa Shoyu Co Ltd Radiosensitizing agent or agent for increasing effect of radiomimetic substance
US4511713A (en) * 1980-11-12 1985-04-16 The Johns Hopkins University Process for selectively controlling unwanted expression or function of foreign nucleic acids in animal or mammalian cells
US4394443A (en) * 1980-12-18 1983-07-19 Yale University Method for cloning genes
US4358586A (en) * 1980-12-23 1982-11-09 Harvey Rubin Detection and isolation of endorphin mRNA using a synthetic oligodeoxynucleotide
DE3106982A1 (de) * 1981-02-25 1982-09-09 Dr. Karl Thomae Gmbh, 7950 Biberach "neues tridecadeoxynukleotid, verfahren zu seiner herstellung und verwendung"
US4464359A (en) * 1981-04-10 1984-08-07 Research Corporation (2'-5')-Oligo (3'-deoxyadenylate) and derivatives thereof
ATE75483T1 (de) * 1981-10-23 1992-05-15 Molecular Biosystems Inc Oligonukleotides heilmittel und dessen herstellungsverfahren.
US4393201A (en) * 1981-11-04 1983-07-12 The Wistar Institute DNA Which codes for glycoprotein of era-strain rabies virus

Also Published As

Publication number Publication date
AU578625B2 (en) 1988-11-03
MTP957B (en) 1985-05-27
AT392081B (de) 1991-01-25
SE466482B (sv) 1992-02-24
DK493584D0 (da) 1984-10-16
BE900827A (fr) 1985-02-15
GB2148302A (en) 1985-05-30
IE842668L (en) 1985-04-17
DE3437852A1 (de) 1985-05-23
GB8425799D0 (en) 1984-11-21
IE57987B1 (en) 1993-06-02
SE8405133D0 (sv) 1984-10-15
ATA329284A (de) 1990-07-15
FR2553420B1 (fr) 1988-04-01
US4689320A (en) 1987-08-25
GB2148302B (en) 1987-10-07
SG31088G (en) 1988-09-30
NL8403163A (nl) 1985-05-17
DK493584A (da) 1985-04-18
PH21629A (en) 1987-12-11
IT1179144B (it) 1987-09-16
IT8468021A1 (it) 1986-04-16
NZ209840A (en) 1988-11-29
LU85594A1 (de) 1985-04-02
CH667593A5 (de) 1988-10-31
DK168061B1 (da) 1994-01-31
FR2553420A1 (fr) 1985-04-19
SE8405133L (sv) 1985-04-18
AU3423984A (en) 1985-04-26

Similar Documents

Publication Publication Date Title
IT8468021A0 (it) Agente anti virale e procedimento per inibire la propagazione di un virus
IT8025713A0 (it) Analoghi di 7-ossabicicloeptano e 7-ossabicicloeptene prostaglandina.
NL930132I1 (nl) Vaccin tegen hepatitis B virus werkwijze en getransformeerde eukaryotische cellen en de bereiding van dat vaccin
IT1194289B (it) Costruzione di torce
IT7968443A0 (it) Procedimento per la preparazione del cloruro di cianurile allo stato solido
GB8505336D0 (en) Preventing propagation of titanium fires
IT1177375B (it) Composizione e procedimento per inibire le incrostazioni
NO843425L (no) Fremgangsmaate for fremstilling av (substituerte) fenyl-alifatisk-isoksazoler for bekjempelse av virus
IT1196107B (it) Agente anti-russamento
JPS5495789A (en) Propagation of rota virus
IT1121914B (it) Procedimento per la preparazione di urochinasi allo stato puro
IT8149759A0 (it) Agenti tensioattivi e loro preparazione
TR22147A (tr) Suekrozun fruktoz ve etanola doenuestueruelmesi
IT1156478B (it) Procedimento per la preparazione di acril e metacril ammidi
IT8320066A0 (it) 6'alchil analoghi della spectinomicina e medoti per la loro preparazione.
IT8249611A0 (it) Preparazione di carbonati di alchilene
IT1196078B (it) Composizione e procedimento per inibire la polimerizzazione di composti vinilaromatici
IT1138579B (it) Sintesi di urea
IT8867697A0 (it) Procedimento per provocare la rottura di una emulsione
BR8304991A (pt) Estrutura de mangueira reforcada e mangueira
IT1153225B (it) Armatura ortopedica per sostenere e mobilizzare gli arti di motulesi
IT1197688B (it) Attivita' antiflogistica,analgesica,antipiretica ed antiaggregante piastrinica di 1-metil-5-metilbenzoilpirrol-2-acetamido acetanilidi
IT1134535B (it) Procedimento e perfezionamento per la preparazione di dicumilperossido
IT1155070B (it) Sintesi di urea
IT1120992B (it) Procedimento per la preparazione del cloruro di cianurile allo stato solido

Legal Events

Date Code Title Description
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19950831